whole blood, serum, white cells, red blood cells, urine, breast milk, meconium

Exposure to Environmental Pollution

Rambam Medical Center

Lis Medical Center

Assaf Harofeh Medical Center

Impact of Exposure to Environmental Pollutants on Birth Outcomes in an Israeli Cohort

assessment of BFRs and phthalates body burdens through measurement of these chemicals in maternal and paternal serum and urine, cord blood, breastmilk and neonatal meconium among several representative sub-populations

To examine associations between exposure to PBDEs and phthalates and (a) pregnancy complications, (b) anthropometrics at birth (i.e. birth weight adjusted for gestational age, ponderal index, head circumference adjusted for gestational age), and (c) cryptorchidism incidence, (d) maternal and infant thyroid function

To establish a bio repository of these media for future studies and to establish follow up methods for this cohort to later assess development and growth in the infants, toddlers and children

Assaf-Harofeh Medical Center

Seminoma

Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy

Carboplatin

Involved node RT

Aachen Universitätsklinik

Berlin Universitätsklinik Charité

Berlin Vivantes - Urban

Berlin Vivantes - Neukölln

Universitaetsklinikum Düsseldorf

Klinik Essen-Mitte

Hamburg Universitätsklinikum - Eppendorf

Krefeld Maria-Hilf Krankenhaus

Universitätsklinikum Köln

Klinikum Harlaching

Universitätsklinikum Tübingen

Universitätsklinikum Ulm

Kantonspital Aarau

Kantonsspital Baden

Universitaetsspital-Basel

Istituto Oncologico della Svizzera Italiana (IOSI)

Inselspital Bern

Spitalzentrum Biel

Kantonsspital Graubuenden

Centre Hospitalier Universitaire Vaudois CHUV

Kantonsspital Olten

Hopital de Sion

Kantonsspital - St. Gallen

Regionalspital Thun

Kantonsspital Winterthur

Therapy De-escalation in Seminoma Stage IIA/B

Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma

PFS is defined as the time from registration until one of the following events occurs:
PD or relapse, defined as progression according to the modified trial-specific version of RECIST 1.1 or a rising level of the tumor marker beta-hCG over the ULN (value must be confirmed by a second measurement). Presence of non-seminoma germ cell tumor has to be excluded in the latter case.
Death from any cause.

AEs are collected from inclusion until 30 days after the end of treatment

AEs will be collected from 30 days after the end of treatment until the end of the follow-up phase

from registration until documented progressive disease, relapse or death due to tumor.

from registration to the date of death from any cause

from registration to the date of death due to seminoma

from registration to the date of failure of PFS

from first localization where recurrent tumor disease is detected

testicular neoplasms/nausea

Impact of Exposure to Environmental Pollutants on Birth Outcomes in an Israeli Cohort

Therapy De-escalation in Seminoma Stage IIA/B

The most complete medicinal herbs database backed by science